PL
VRNA

Parkwood LLC’s Verona Pharma VRNA Stock Holding History

Parkwood LLC’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,953
Closed -$277K – 204
2023
Q4 		$277K Sell
13,953
-1,092
-7% -$16.1K 0.03% 120
2023
Q3 		$245K Sell
15,045
-2,121
-12% -$40.8K 0.03% 123
2023
Q2 		$363K Sell
17,166
-1,712
-9% -$36.5K 0.07% 115
2023
Q1 		$379K Buy
+18,878
New +$408K 0.05% 125

Other funds holding VRNA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Parkwood LLC's VRNA Position: Q1 2024 in Review

Parkwood LLC sold out of Verona Pharma (VRNA) in Q1 2024, closing a stake of 13,953 shares — an estimated $277K sold.

Parkwood LLC first reported a position in VRNA in Q1 2023 and held it in 4 quarters. The position peaked at $379K in Q1 2023. 113 funds tracked by Wall St. Rank hold VRNA as of Q1 2024.

  • Parkwood LLC reported no remaining Verona Pharma position as of Q1 2024 after selling out during the quarter.
  • Parkwood LLC sold 13,953 Verona Pharma shares in Q1 2024, an estimated $277K.
  • Parkwood LLC first reported a position in Verona Pharma in Q1 2023 and held it in 4 quarters.
  • Parkwood LLC's Verona Pharma position peaked at $379K in Q1 2023.
  • 113 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2024.

Based on Parkwood LLC's 13F filing for Q1 2024, filed 15 May 2024.